Studies with Avian Influenza A Viruses: Cross Protection Experiments in Chickens

Allan, W. H.; Madeley, C. R.; Kendal, Alan P.

doi:10.1099/0022-1317-12-2-79

Cited by 52 publications

(19 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The exploration of NA as a vaccine antigen for influenza virus is limited compared to that of HA, despite early evidence that serum antibodies specific for NA are associated with protection from influenza virus infection (11,12,(38)(39)(40). Neuraminidase is immunologically subdominant to HA (8,41).…”

Section: Discussionmentioning

confidence: 99%

Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge

Mooney

Gabbard

et al. 2017

J Virol

View full text Add to dashboard Cite

Seasonal human influenza virus continues to cause morbidity and mortality annually, and highly pathogenic avian influenza (HPAI) viruses along with other emerging influenza viruses continue to pose pandemic threats. Vaccination is considered the most effective measure for controlling influenza; however, current strategies rely on a precise vaccine match with currently circulating virus strains for efficacy, requiring constant surveillance and regular development of matched vaccines. Current vaccines focus on eliciting specific antibody responses against the hemagglutinin (HA) surface glycoprotein; however, the diversity of HAs across species and antigenic drift of circulating strains enable the evasion of virus-inhibiting antibody responses, resulting in vaccine failure. The neuraminidase (NA) surface glycoprotein, while diverse, has a conserved enzymatic site and presents an appealing target for priming broadly effective antibody responses. Here we show that vaccination with parainfluenza virus 5 (PIV5), a promising live viral vector expressing NA from avian (H5N1) or pandemic (H1N1) influenza virus, elicited NA-specific antibody and T cell responses, which conferred protection against homologous and heterologous influenza virus challenges. Vaccination with PIV5-N1 NA provided cross-protection against challenge with a heterosubtypic (H3N2) virus. Experiments using antibody transfer indicate that antibodies to NA have an important role in protection. These findings indicate that PIV5 expressing NA may be effective as a broadly protective vaccine against seasonal influenza and emerging pandemic threats.IMPORTANCE Seasonal influenza viruses cause considerable morbidity and mortality annually, while emerging viruses pose potential pandemic threats. Currently licensed influenza virus vaccines rely on the antigenic match of hemagglutinin (HA) for vaccine strain selection, and most vaccines rely on HA inhibition titers to determine efficacy, despite the growing awareness of the contribution of neuraminidase (NA) to influenza virus vaccine efficacy. Although NA is immunologically subdominant to HA, and clinical studies have shown variable NA responses to vaccination, in this study, we show that vaccination with a parainfluenza virus 5 recombinant vaccine candidate expressing NA (PIV5-NA) from a pandemic influenza (pdmH1N1) virus or highly pathogenic avian influenza (H5N1) virus elicits robust, cross-reactive protection from influenza virus infection in two animal models. New vaccination strategies incorporating NA, including PIV5-NA, could improve seasonal influenza virus vaccine efficacy and provide protection against emerging influenza viruses.KEYWORDS influenza, vaccine, neuraminidase, parainfluenza virus 5, highly pathogenic avian influenza virus

show abstract

Section: Discussionmentioning

confidence: 99%

Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge

Mooney

Gabbard

et al. 2017

J Virol

View full text Add to dashboard Cite

show abstract

“…Expt. 1 also illustrated the protective capacity of antibody to the H antigen (Allan et al, 1971). The lack of protection in Expts.…”

Section: Methodsmentioning

confidence: 99%

“…However, the use of a vaccine virus with the same H antigen as the field virus interferes with serological diagnosis by HI tests. There is evidence that antibodies to N also confer resistance to challenge with highly pathogenic influenza viruses in chickens (Allan et al, 1971;Rott et al, 1974). N-specifîc vaccines, i.e.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of avian influenza Neuraminidase‐specific vaccines in chickens

1986

View full text Add to dashboard Cite

SUMMARYThis paper investigates the protection induced in chickens by live neuraminidase (N)-specific vaccines against highly pathogenic avian influenza. Vaccination with viruses belonging to N1 and N8 subtypes protected against challenge with virulent viruses of the same N subtype and irrelevant haemagglutinin (H) subtypes. The main advantage of Nspecific vaccines is that they do not confuse serological diagnosis by haemagglutination inhibition tests. The anomalous cross-protection between influenza viruses of H1 and H5 subtypes could be exploited to control outbreaks caused by highly pathogenic H5 viruses by using vaccines based on H1 and the appropriate N.

show abstract

“…Three-month-old SPF Leghorn chicks were inoculated (following Allan et al, 1971) with strain A/FPV/Dutch/27, in order to obtain positive control sera. Negative control sera were obtained from untreated chicks under the same conditions.…”

Section: Control Sera For Elisa Testmentioning

confidence: 99%

Type a influenza viruses in birds in southern Spain: Serological survey by enzyme‐linked immunosorbent assay and haemagglutination inhibition tests

et al. 1990

View full text Add to dashboard Cite

show abstract

Studies with Avian Influenza A Viruses: Cross Protection Experiments in Chickens

Cited by 52 publications

References 9 publications

Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge

Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge

Efficacy of avian influenza Neuraminidase‐specific vaccines in chickens

Type a influenza viruses in birds in southern Spain: Serological survey by enzyme‐linked immunosorbent assay and haemagglutination inhibition tests

Contact Info

Product

Resources

About